After Fulcrum Therapeutics disclosed full Cohort 4 data from the Phase Ib PIONEER study for pociredir in sickle cell disease, Truist notes that mean absolute HbF was 19.3% and treatment delta was 12%, striking management's anticipated outcomes. "Encouragingly," oral pociredir continues to show a consistent safety and tolerability profile, adds the analyst, who would remain buyers of shares on any weakness and maintains a Buy rating and $18 price target on the "under-the-radar story."
